Current Topics in Medicinal Chemistry

Preface by Christopher J. Dinsmore (Hot Topic: Farnesyl-Protein Transfrase Inhibitors Guest Editor: Christopher J. Dinsmore
pp. i-i(1)
Author: J. Dinsmore, C.

Preface by Guo Zhu Zheng
pp. i-i(1)
Author: Zhu Zheng, G.

Use of Synthetic Isoprenoid Analogues for Understanding Protein Prenyltransferase Mechanism and Structure
pp. 1043-1074(32)
Authors: Kale, T.A.; Hsieh, S-a.J.; Rose, M.W.; Distefano, M.D.

Inhibitors of Farnesyltransferase and Geranylgeranyltransferase-I for Antitumor Therapy: Substrate-Based Design, Conformational Constraint and Biological Activity
pp. 1075-1093(19)
Authors: Dinsmore, C.J.; Bell, I.M.

Farnesyl Protein Transferase Inhibitor ZARNESTRA™ R115777 - History of a Discovery
pp. 1095-1102(8)
Authors: Venet, M.; End, D.; Angibaud, P.

Sch-66336 (Sarasar®) and Other Benzocycloheptapyridyl Farnesyl Protein Transferase Inhibitors: Discovery, Biology and Clinical Observations
pp. 1103-1114(12)
Authors: Taveras, A.G.; Kirschmeier, P.; Baum, C.M.

G-Protein Coupled Receptor Antagonists-1: Protease Activated Receptor-1 (PAR-1) Antagonists as Novel Cardiovascular Therapeutic Agents (Hot Topic: Structure and property Approaches in Recent Drug Discovery Guest Editor: Guo Zhu Zheng)
pp. 1115-1123(9)
Author: Chackalamannil, S.

The Role of Absorption, Distribution, Metabolism, Excretion and Toxicity in Drug Discovery
pp. 1125-1154(30)
Authors: Lin, J.; Sahakian, D.C.; de Morais, S.M.; Xu, J.J.; Polzer, R.J.; Winter, S.M.

Structure-Activity Relationship Studies: M2 and CCR5 Receptor Antagonists
pp. 1155-1169(15)
Authors: Boyle, C.D.; Palani, A.

Theoretical Property Predictions
pp. 1171-1192(22)
Author: Livingstone, D.J.